Brown Advisory
ALXN

Brown Advisory’s Alexion Pharmaceuticals ALXN Stock Holding History

Brown Advisory’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,403
Closed -$626K – 1163
2021
Q2 		$626K Sell
3,403
-53
-2% -$9.1K ﹤0.01% 802
2021
Q1 		$528K Buy
3,456
+740
+27% +$114K ﹤0.01% 830
2020
Q4 		$424K Buy
2,716
+377
+16% +$48.4K ﹤0.01% 811
2020
Q3 		$268K Sell
2,339
-2,609
-53% -$281K ﹤0.01% 839
2020
Q2 		$555K Buy
4,948
+1,218
+33% +$129K ﹤0.01% 707
2020
Q1 		$336K Buy
3,730
+1,559
+72% +$153K ﹤0.01% 762
2019
Q4 		$236K Sell
2,171
-56
-3% -$5.99K ﹤0.01% 942
2019
Q3 		$218K Sell
2,227
-51
-2% -$5.75K ﹤0.01% 932
2019
Q2 		$298K Sell
2,278
-15,833
-87% -$2.04M ﹤0.01% 872
2019
Q1 		$2.45M Buy
18,111
+4,418
+32% +$549K 0.01% 588
2018
Q4 		$1.33M Sell
13,693
-10,106
-42% -$1.19M ﹤0.01% 691
2018
Q3 		$3.31M Buy
23,799
+3,538
+17% +$444K 0.01% 538
2018
Q2 		$2.52M Buy
20,261
+15,169
+298% +$1.77M 0.01% 578
2018
Q1 		$567K Buy
5,092
+259
+5% +$31K ﹤0.01% 800
2017
Q4 		$577K Sell
4,833
-2,007
-29% -$244K ﹤0.01% 837
2017
Q3 		$960K Sell
6,840
-7,562
-53% -$1.03M ﹤0.01% 672
2017
Q2 		$1.75M Sell
14,402
-2,494,322
-99% -$290M 0.01% 558
2017
Q1 		$304M Sell
2,508,724
-727,210
-22% -$93.8M 1.04% 30
2016
Q4 		$396M Sell
3,235,934
-636,832
-16% -$77.9M 1.41% 16
2016
Q3 		$475M Buy
3,872,766
+825,135
+27% +$106M 1.63% 14
2016
Q2 		$356M Buy
3,047,631
+581,703
+24% +$82.5M 1.25% 23
2016
Q1 		$343M Buy
2,465,928
+232,397
+10% +$34.1M 1.19% 29
2015
Q4 		$426M Buy
2,233,531
+335,663
+18% +$58.6M 1.45% 23
2015
Q3 		$297M Buy
1,897,868
+383,966
+25% +$70M 1.06% 28
2015
Q2 		$274M Buy
1,513,902
+1,460,505
+2,735% +$252M 0.89% 32
2015
Q1 		$9.25M Buy
+53,397
New +$9.67M 0.03% 287

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Brown Advisory's ALXN Position: Q3 2021 in Review

Brown Advisory sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,403 shares — an estimated $626K sold.

Brown Advisory first reported a position in ALXN in Q1 2015 and held it in 26 quarters. The position peaked at $475M in Q3 2016. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Brown Advisory reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Brown Advisory sold 3,403 Alexion Pharmaceuticals shares in Q3 2021, an estimated $626K.
  • Brown Advisory first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 26 quarters.
  • Brown Advisory's Alexion Pharmaceuticals position peaked at $475M in Q3 2016.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Brown Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.